Pinpoint Genomics
Life Tech Continues to Gather Evidence Backing NSCLC Dx Pervenio, As Commercialization Progresses
Premium
In marketing its newly launched Pervenio lung cancer prognostic test, Life Technologies' sales force is targeting specialist thoracic surgeons and medical oncologists in 48 US states.
Life Technologies this week launched Pervenio Lung RS – a quantitative PCR-based assay for lung cancer prognosis that gauges the expression of 14 genes – through its CLIA lab in Sacramento, Calif.
This story has been updated from a previous version to include additional information about the QuantStudio Dx platform.
Following CLIA Lab Buy, Life Tech Jumps into MDx Space with Purchase of Pinpoint, Lung Cancer Dx
Premium
After garnering a CLIA-certified clinical laboratory through its purchase of Navigenics last week, Life Technologies wasted no time jumping into the molecular diagnostics space.
Life Technologies Acquires Lung Cancer Test Developer Pinpoint Genomics
NEW YORK (GenomeWeb News) – Life Technologies said today that it has acquired Pinpoint Genomics and its early-stage non-small cell lung cancer test designed to help doctors identify early-stage patients at high risk for progression to late-stage disease.
Feb 15, 2012